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ABSTRACT 
 
Introduction: Lymphatic filariasis (LF) is the world's second leading cause of long-term disability. According to 
the World Health Organization, India, Indonesia, Nigeria and Bangladesh alone contribute about 70% of the 
infection worldwide. Mass drug administration of one annual dose of diethylcarbamazine citrate and albendazole is 
currently advocated by WHO for control of lymphatic filariasis. The state of Madhya Pradesh (MP), India adopted 
MDA for elimination of LF in 2004. The aim of this study was to assess the effective coverage of MDA and to 
determine the causes of coverage compliance gap. Methodology: It was a cross-sectional survey in which both 
quantitative and qualitative data was collected from the study clusters by house-to-house surveys. Multistage 
random sampling method was used to select the clusters. 30 household were covered in each cluster, covering 4 
clusters per district; so in each district 120 households were surveyed. Results: The present study was conducted in 
three filariasis endemic districts of Madhya Pradesh. The study covered a target population of 1863 from twelve 
clusters of which 94.09% (1753) were eligible for drug consumption. The overall drug distribution rate (coverage) 
was 84.59% and the coverage compliance gap was 16.82%. Overall drug ingestion compliance was 80.10%. The 
overall effective coverage was 67.77% (Z Score=3.6338, p=0.00014). The drug distribution rate (coverage) was 
much better in urban areas (92.55%) as compared to rural areas (82.45%) and therefore the effective coverage was 
much better in urban areas (75.53%) as against 65.65% in the rural areas. The most important reason of non-
compliance was lack of awareness about the disease (47.45%). Understaffing was also reported in all the districts 
and impact assessment data was not collected in any of the three districts. Conclusion: There is need of intensive 
health education campaigns to increase the level of scientific information about the disease. The coverage activities 
should be prioritized equally with Behavior Change Communication (BCC) activities. The timings of drug 
distribution should be properly thought out. 
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Introduction 
 
Lymphatic filariasis (LF) is a parasitic disease, 
commonly known as elephantiasis which is caused by 
thread like worms known as filarial parasite. The adult 
worms (male and female) settle in lymph nodes and the 
female worm gives birth to millions of young ones 
known as microfilariae (mf)[1]. 
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Lymphatic filariasis (LF) is the world's second leading 
cause of long-term disability. The current estimate 
reveals that 120 million people in 83 countries of the 
world are infected with LF parasites and more than 
20% of the world's populations are at risk of acquiring 
infection[2]. 
Over 40 million people are severely disfigured and 
disabled by filariasis and 76 million are apparently 
normal but have hidden internal damage to lymphatic 
and renal systems. According to the World Health 
Organization, India, Indonesia, Nigeria and Bangladesh 
alone contribute about 70% of the infection worldwide. 
It has been estimated that approximately 5 million 
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Disability Adjusted Life Years (DALYs) lost annually, 
ranking third among the TDR diseases in terms of 
DALYs after malaria and TB. In addition, the social 
and psychological impact is enormous - often 
destroying marriages and family relationships[3]. 
The Government of India is signatory to the World 
Health Assembly Resolution in 1997 for Global 
Elimination of Lymphatic Filariasis. The National 
Health Policy (2002) envisages elimination of 
lymphatic filariasis in India by 2015[4]. 
The Strategy for Elimination of Lymphatic Filariasis 
includes Annual Mass Drug Administration (MDA) 
of single dose of DEC (Diethylcarbamazine citrate) and 
Albendazole for 5 years or more to the eligible 
population (except pregnant women, children below 2 
years of age and seriously ill persons) to interrupt 
transmission of the disease and Home based 
management of lymphoedema cases and up-scaling of 
hydrocele operations in identified CHCs/ 
Districthospitals /medical colleges[4]. 
 
Mass drug administration of one annual dose of 
diethylcarbamazine citrate and albendazole is currently 
advocated by WHO for control of lymphatic filariasis 
in several endemic countries, since this combination 
is more effective than either drug administered alone. 
Reactions induced by diethylcarbamazine citrate such 
as fever, headache, myalgia, anorexia, abdominal 
discomfort, and so on, are not uncommon in 
microfilaraemic patients, the severity and duration of 
which are directly related to microfilarial density in the 
host. Although these reactions arise in a small 
proportion of cases and are easily managed 
in controlled clinical trials, they can lead 
to panic reactions among people when the drug is given 
to millions of patients by health workers, which might 
jeopardise the control programme[5].   
In Madhya Pradesh, the disease has been endemic in 
eleven districts. The state of Madhya Pradesh (MP), 
India adopted MDA for elimination of LF in 2004. The 
endemic districts have been included under NVBDCP 
and there have been regular distribution of Di-ethyl 
Carbamazine (DEC) tablets in these districts. The first 
round of MDA in MP was carried out in June 2004.  
 
Evaluation of the MDA activities has been an integral 
part of the strategy for filariasis elimination so as make 
an independent assessment of the program 
implementation with respect to process and outcome 
indicators. The evaluation helps to review the progress 
of activities of single dose of DEC and Albendazole 
administration in filariasis endemic districts and to 
suggest mid-course correction and necessary steps for 
further action.  
 
The aim of this study was to assess the effective 
coverage of single dose DEC plus Albendazole tablets 
in the filariasis endemic districts and to determine the 
causes of coverage compliance gap. 
 
Methodology 
In 2012, Mass Drug Administration (MDA) was 
carried in the three districts included in this study on 
April 22. This was followed by midterm evaluation of 
MDA in the three districts from June 09 2012-June 20 
2012. It was a cross-sectional survey in which both 
quantitative and qualitative data was collected by on 
site observations and detailed interviews in the 
community. 
Selection of the clusters and sample size 
The standard guidelines for MDA required that a total 
of 30 household be covered in each cluster, covering 4 
clusters per district. Therefore, keeping in the mind the 
standard procedure, in each district 120 households 
were surveyed. Multistage random sampling method 
was used to select the clusters. 
The MDA assessment was carried out in both rural and 
urban areas in all three districts, as per the standard 
methodology. For evaluation of MDA activities in a 
district, all the PHCs in a district were stratified into 
three groups on the basis of reported MDA coverage of 
previous year- PHCs with coverage below 50%, 
between 50-80% above 80%. 
In rural areas, a PHC from each category was selected 
for MDA evaluation; in case there was no PHC in a 
particular category, two PHCs from the next category 
were selected. In the next step, from each category of 
the PHCs, one PHC was selected randomly. 
Afterwards, from each of the selected PHC one village 
was selected randomly using currency note for random 
number generation for household survey. In each 
village, 30 household were covered using standard 
questionnaires developed for MDA evaluation.  
In the urban areas, the complete list of the wards was 
arranged. Thereafter, one ward was selected randomly 
for the evaluation of the programme, using currency 
note for random number generation. In the next step, in 
each selected ward 30 household were covered. 
The survey teams visited the study clusters and 
collected both qualitative and quantitative data to make 
independent assessment. The assessment was carried 
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out as per the standard methodology and standard 
proforma developed by National Institute of 
Communicable Diseases, Delhi. 
Data was collected by house-to-house surveys with the 
use of standard proforma and from district health 
authorities and it was thoroughly scrutinized and 
analyzed manually and P value and Z score was 
calculated using Z test calculator[12]. 
Results 
The present study was conducted in three of the eleven 
districts of Madhya Pradesh which are known for 
filariasis endemicity- namely Tikamgarh, Chatarpur 
and Panna. The study covered a target population of 
1863 from twelve clusters of which 94.09% (1753) 
were eligible for drug consumption. Children below 
two years age, pregnant women and severely ill 
patients are ineligible for drug ingestion as per the 
guidelines.  
The survey was conducted to find out the drug 
distribution rate/coverage (i.e. how many people 
received the tablets) and the coverage compliance gap 
(i.e. number of people who ingested sufficient dose of 
DEC tablets out of total population who had received 
the DEC tablets) and to find out the effective coverage 
(i.e. number of people who ingested sufficient dose of 
DEC tablets out of total eligible population). The 
survey also sought the reasons for non-compliance. 
District-wise analysis revealed wide variations among 
districts and between urban and rural areas within same 
district. Out of 610 people surveyed in the Tikamgarh 
district, the eligible population was 92.29%. The drug 
distribution rate (coverage) was 82.01% and the 
coverage compliance gap was 18.60%. Overall drug 
ingestion compliance was 77.28% ranging from 82.35 
in urban areas to below 80% in rural areas. The 
effective coverage in Tikamgarh district was 63.41%. 
(Table 1) 
Out of 663 people surveyed in Chatarpur district, the 
eligible population was 95.17%. The drug distribution 
rate (coverage) was 90.02% and the coverage 
compliance gap was 14.11%. Overall drug ingestion 
compliance was 84.33%. The effective coverage in 
Chatarpur district was 75.91%. (Table 2) 
Out of 590 people surveyed in Panna district, the 
eligible population was 94.74%. The drug distribution 
rate (coverage) was 81.03% and the coverage 
compliance gap was 18.14%. Overall drug ingestion 
compliance was 77.70%. The effective coverage in 
Panna district was 62.97%. (Table 3) 
As expected, the drug distribution rate (coverage) was 
much better in urban areas (92.55%) as compared to 
rural areas (82.45%) and therefore the effective 
coverage was much better in urban areas (75.53%) as 
against 65.65% in the rural areas. However the 
coverage compliance gap was slightly higher in urban 
clusters (17.02%) as compared to rural clusters 
(16.77%). (Table 4) 
Of the total 1853 population surveyed in this study, 
1753 were eligible for drug consumption. The overall 
drug distribution rate (coverage) was 84.59% and the 
coverage compliance gap was 16.82%. Overall drug 
ingestion compliance was 80.10%. The overall 
effective coverage was 67.77%. (Table 5) 
Chatarpur district turned out to be the best performing 
district with an overall effective coverage of 75.91%. 
(Table 5) 
Table No. 1: District Tikamgarh 
Name of Cluster Total Sampled 
Population 
Eligible Population 
(%) 
Drug Distribution 
Rate (Coverage) (%) 
Drug Ingested 
(Compliance) (%) 
Bhagat Nagar 
Colony (Urban) 
141 132(93.61) 119(90.15) 98(82.35) 
Badagaon 178 161(89.94) 121(75.15) 93(76.86) 
Baldevgarh 167 150(93.75) 124(82.67) 89(71.77) 
Jatara 176 120(92.30) 98(81.66) 77(78.57) 
Total 610 563(92.29) 462(82.01) 357(77.28) 
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Table No. 2: District Chhatarpur 
 
Name of Cluster Total Sampled 
Population 
Eligible Population  
(%) 
Drug Distribution 
Rate (Coverage) (%) 
Drug Ingested 
(Compliance) (%) 
Ayodhya Nagar 
Basti (Urban) 
149 140(93.95) 132(94.28) 105(79.55) 
Rajnagar 197 191(96.95) 168(87.95) 153(91.08) 
Satai 169 161(95.26) 148(91.92) 135(91.22) 
Ishanagar 148 139(93.91) 120(86.34) 86(71.66) 
Total 663 631(95.17) 568(90.02) 479(84.33) 
 
Table No. 3: District Panna 
 
Name of Cluster Total Sampled 
Population 
Eligible 
Population  
(%) 
Drug Distribution 
Rate (Coverage) (%) 
Drug Ingested 
(Compliance) (%) 
Sinchai Nagar/Civil 
Lines (Urban) 
110 104(94.54) 97(93.27) 81(83.51) 
Devendranagar 141 134(93.59) 127(94.78) 112(88.19) 
Ajaygarh 153 146(90.40) 111(76.03) 75(67.57) 
Pawai 186 175(94.37) 118(67.43) 84(71.20) 
Total 590 559(94.74) 453(81.04) 352(77.70) 
 
Table No. 4 (a): Urban and Rural distribution 
 
Area Total 
Sampled 
Population 
Eligible 
Population 
(%) 
Drug 
Distribution 
Rate 
(Coverage) 
(%) 
Drug Ingested 
(Compliance) 
(%) 
Coverage 
Compliance 
Gap 
(%) 
Effective 
Coverage 
(%) 
Urban 400 376 (94.00) 348 
(92.55) 
284 
(81.61) 
17.02 75.53 
Rural 1463 1377 (94.12) 1135 (82.42) 904 (79.64) 16.77 65.65 
Total 1863 1753 (94.09) 1483 (84.59) 1188 (80.10) 16.82 67.77 
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Table No. 4 (b): Urban and Rural distribution 
 
Variable Drug Ingested 
(Compliance) 
Effective 
Coverage 
Z Score 0.802 3.6338 
P value 0.4237 0.00014 
 
Table No. 5: District wise distribution 
 
Name of District 
(Total Sampled 
Population) 
Eligible 
Population 
(%) 
Drug Distribution 
Rate (Coverage) 
(%) 
Drug Ingested 
(Compliance) 
(%) 
Coverage 
Compliance 
Gap 
(%) 
Effective 
Coverage  
(%) 
Tikamgarh 
(610) 
563 
(92.29) 
462 
(82.01) 
357 
(77.28) 
18.60 63.41 
Chatarpur  
(663) 
631  
(95.17) 
568 
(90.02) 
479 
(84.33) 
14.11 75.91 
Panna  
(590) 
559 
(94.74) 
453 
(81.03) 
352 
(77.70) 
18.14 62.97 
Total  
(1863) 
1753 1483 
(84.59) 
1188 
(80.10) 
16.82 67.77 
 
Table No. 6: Reasons of Non Compliance 
 
Reason % of Respondents 
(n=295) 
Lack of awareness 47.45 
Improper counseling 18.98 
Not available at home 11.52 
Fear of side effects 08.81 
Forgot to consume the drug 07.79 
Others 05.42 
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Very few people had ingested the drug in presence of 
distributor. Many families reported that the distributors 
just provided the drugs and no information about 
timing and method of drug ingestion was given. This 
appears to be the main reason of coverage compliance 
gap. 
According to our study, the most important reason of 
non-compliance was lack of awareness about the 
disease (47.45%). Many people did not know the 
reason for ingesting the drug. The other important 
reason was improper counseling (18.98%) as many 
people complained that they were not explained when 
and how the drug should be ingested. 11.52% people 
said that they were not at home when the drug 
distributors came to their locality. 08.81% people said 
that they feared side effects of the drugs (some of them 
had suffered from side effects in previous years after 
taking these drugs) and 07.79% said that they forgot to 
take the drugs. 
Trainings were organized at all level right from district 
to sub-centre level in all the three districts for Medical 
officers, paramedical workers, drug distributors and lab 
technicians. However there was no system found for 
the quality check of these trainings. 
Understaffing was also reported at all the level i.e. 
Medical officers, paramedical workers, drug 
distributors, lab technicians. However it was more 
prominent in the staff of morbidity management where 
still large numbers of posts were vacant. 
The DEC distribution is a main activity in MDA 
program. To make drugs available is a significant and 
integral activity for this work. Moreover record of 
previous year consumption, balance of drug and 
calculation of present year demand was properly 
maintained. However no record on quality check was 
recovered.  
The impact assessment is done by the local authorities 
to understand the effect of the MDA. The drug 
distribution rounds to see the effect. Indicators like Mf 
Rate etc are used to see the before and after conditions. 
However, no such data was collected in any of the 
three districts.  
The IEC which is instrumental for the awareness 
generation and active participation of the community 
forms an important part of the strategy. All three 
districts offices reported to have spent money on 
preparation of wall paintings and printing of IEC 
materials like pamphlets, posters, banners etc. 
Loudspeakers were also used as IEC mode. 
However, at the time of fields visits for verification by 
the monitoring teams, majority of respondents from 
both rural and urban area said that they have seen 
things regarding MDA and filariasis in the form of 
banner and posters; few of them also reported reading 
pamphlets and wall paintings were also seen only in 
few areas. 
All the IEC activities provided very limited 
information to make community aware of the possible 
side effects. During the field visits it was found that at 
the time of drug distribution health worker were not 
adequately giving the health education to the 
recipients, which if was given then coverage could 
have been better. Ironically some interesting things 
were also noticed like, in some villages even the health 
worker and teacher wasn’t fully aware about filariasis 
and it definitely raises the query regarding their 
training quality. 
A very less proportion of covered populations have 
reported any side effect after ingestion of drug, and if 
so it was mostly nausea and vomiting & fever. The one 
thing, which was missing from all the evaluation areas, 
was that although drugs were distributed to the 
population en mass, only a small proportion was told 
about the side effects and its management. The side 
effects were properly recorded only in limited number 
of cases. Very few people were given management for 
side effects. 
The mechanism for management of side effects was 
grossly missing in the majority of the areas in all three 
districts. The people had to go to private practitioners 
and quacks in some cases for the management of side 
effects, where they had to spent money out of their own 
pocket as they were not referred to PHC or other 
medical facility by the health functionaries. The level 
of awareness about the morbidity management in the 
community was very low.  
Discussion 
MDA should be implemented in >85% of the 
population in endemic areas and must be sustained for 
5 years to be successful[9].   In this survey, the 
effective coverage was 67.77% which was way below 
the standard target. Ideally the coverage compliance 
gap should be zero but in our survey it was higher than 
14% in all the districts. 
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In our study, the effective coverage rates were higher 
in urban areas in all the districts. In a study done in 
West Bengal, the effective coverage rate was 
significantly lower in urban than in the rural clusters 
(87.4% vs. 95.3%; z = 3.57, P < 0.01)[6].  
In the same study, Coverage compliance gap was 
higher in urban (5.7%) than in rural cluster (3.9%). In 
our study, the coverage compliance gap was slightly 
higher in urban areas (17.02% vs. 16.77%)[6]. 
In a study done in Gujarat, the coverage rate was 
85.2% with variation across different areas. The 
compliance with drug ingestion was 89% with a gap of 
11%. The effective coverage (75.8%) was much below 
the target (85%)[11]. 
In the present study, lack of awareness was the most 
important cause of non-compliance. In a study done in 
Karnataka, 55% non compliant population said they 
were not at home during MDA activity and 19% did 
not consume the drug because of fear of side effects. 
This compliance rate was poor in urban area (46%) 
compared with rural area (74%). In a study done in 
West Bengal, fear of side-effects was the main reason 
for non-compliance [6-7]. In a study done in Kenya, 
the most prominent reasons given for not taking drugs 
were not being aware of the MDA and drug distributors 
not visiting the household [8]. In a study done in 
Kerala, the important reasons of non compliance were 
client attitude of not perceiving the need and low 
acceptability of drug administrator [10]. 
Conclusion 
The awareness about the Lymphatic Filariasis in the 
population studied is limited to knowing about the 
presence of the disease in the community and most of 
this has generated due the cases in their neighborhood 
and the community. There is need of intensive health 
education campaigns to increase the level of scientific 
information about the disease amongst the affected 
populations. The coverage activities should be 
prioritized equally with Behavior Change 
Communication (BCC) activities as the goal of this 
program is effective coverage and not the actual 
coverage. The timings of drug distribution should be 
properly thought out so that atleast absenteeism part of 
non-compliance can be eliminated. There is a need for 
quality assurance of the activities on MDA by 
monitoring teams in the field so as to eliminate the 
coverage compliance gap. 
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